Bristol-Myers Squibb Stock - Long-term pipeline and business model under review
20.06.2026 - 11:21:28 | ad-hoc-news.de
Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 09:20 UTC. Details in the imprint.
Bristol-Myers Squibb (US1078421011) remains a core name in large-cap pharma as investors assess how its long-term business model can offset looming patent expiries. The focus is increasingly on the depth of its oncology and immunology pipeline rather than short-term quarterly swings.
Background and price data on Bristol-Myers Squibb stock
Key figures, news and filings help investors track how Bristol-Myers Squibb navigates its transition from mature blockbusters to a new generation of therapies.
How Bristol-Myers makes its money
Bristol-Myers Squibb generates the bulk of its revenue from branded prescription drugs, with oncology, hematology and cardiovascular therapies as core pillars. Opdivo for cancer and Eliquis for stroke prevention remain the company’s largest products by sales.
In its most recently reported full year, Bristol-Myers posted revenue of around $45.0 billion, with roughly two-thirds coming from oncology and cardiovascular franchises according to company filings. The business also includes immunology treatments and a smaller but growing cell therapy segment.
Patent cliffs and diversification strategy
A central challenge in the long-term model is the patent cycle. Key products such as Eliquis face loss of exclusivity in the US later this decade, which could pressure revenue and margins as generic competition emerges.
Management seeks to offset this with a broad pipeline and recent acquisitions, adding late-stage assets in oncology and immunology. The company has highlighted more than a dozen potential launches between the mid-2020s and early 2030s as new growth drivers.
Long-term pipeline and R&D focus
Bristol-Myers consistently spends a high single-digit to low double-digit percentage of revenue on research and development, underlining the importance of replenishing its portfolio. Checkpoint inhibitors, cell therapies and targeted small molecules are key areas of focus.
Pipeline assets include next-generation oncology treatments that build on Opdivo’s immuno-oncology platform and expanded indications in immunology diseases, according to recent pipeline overviews. These projects are meant to smooth earnings through and beyond major patent expiries.
Balance sheet, cash generation and capital allocation
The company typically generates strong operating cash flow from its established brands, which supports a regular dividend and ongoing share repurchases. Net debt has been managed downward following prior large acquisitions, improving balance sheet flexibility over time.
According to recent company presentations, management prioritizes funding internal R&D, maintaining a competitive dividend and pursuing bolt-on deals that complement its existing therapeutic areas. This capital allocation framework is central to its long-term equity story.
The product behind the stock
One of Bristol-Myers Squibb’s flagship products is Opdivo, an immuno-oncology drug used to treat various cancers including lung, melanoma and kidney cancer. Opdivo works by helping the immune system recognize and attack cancer cells, and remains a key revenue contributor.
Where the stock trades today
The shares of Bristol-Myers Squibb (US1078421011) trade on the New York Stock Exchange under the ticker BMY; the most recently available closing price was $54.10 on 06/18/2026 in US trading.
Key facts on Bristol-Myers Squibb stock
- Company: Bristol-Myers Squibb Co.
- ISIN: US1078421011
- WKN: 850501
- Ticker: BMY
- Venue: NYSE
- Price (as of 06/18/2026, 15:59 Eastern): 54.10 USD
- Market cap: 110,000,000,000 USD (as of 06/18/2026, rounded)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
